Brief: Cereno Scientific Announces Positive Topline Results Of Phase Iia Trial With Lead Candidate Cs1 In Pulmonary Arterial Hypertension
27/09/2024 19:42
Sept 27 (Reuters) - Cereno Scientific AB CRNOSb.ST :
* CERENO SCIENTIFIC ANNOUNCES POSITIVE TOPLINE RESULTS OF
PHASE
IIA TRIAL WITH LEAD CANDIDATE CS1 IN PULMONARY ARTERIAL
HYPERTENSION
* CERENO SCIENTIFIC AB- CS1 - PHASE IIA SAFETY DATA -
PRIMARY
ENDPOINT OF SAFETY AND TOLERABILITY MET SUCCESSFULLY
Source text for Eikon: ID:nWkr35GSV0
Further company coverage: CRNOSb.ST
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
Brief: Cereno Scientific Reports Positive Results From Study
Brief: Cereno Scientific Q2 Net Sales Sek 0
Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 30.5 Mln